About NORTION
Noah's Ark Carrying Medical Technology
In April 2021, Nortion Medical's Composite Steep Pulse Therapy Device for the ablation treatment of prostate tumors officially obtained the Class III Medical Device Registration Certificate issued by the National Medical Products Administration (NMPA). This product utilizes high-frequency pulsed electric field ablation for prostate cancer treatment. In September 2023, the "Nortion IRE® BPH" composite steep pulse therapy device for treating Benign Prostatic Hyperplasia (BPH) received the NMPA Class III medical device certificate, marking the first Class III device certificate for a BPH treatment based on IRE technology. In 2024, the company's products received the FDA's Breakthrough Device designation and the CE mark for prostate cancer in the EU. The same year, the products were recognized by the Shanghai Municipal Commission of Economy and Informatization and included in Shanghai's "Innovative Product Recommendation Catalog" and "New and Excellent Pharmaceuticals and Medical Devices Catalog." In January 2025, the composite steep pulse therapy device and disposable ablation electrode needle achieved a significant breakthrough in Indonesia, successfully obtaining the Import Medical Device Distribution License issued by the Government of the Republic of Indonesia. In December 2025, the product received the Import Medical Device Distribution License from the Turkish Medicines and Medical Devices Agency. In the same month, the composite steep pulse therapy device officially received NMPA approval for the "ablation treatment of malignant solid liver tumors."
Nortion Medical is a National-level Specialized, Refined, Distinctive, and Innovative ("Little Giant") Enterprise, a National High-Tech Enterprise, as well as a Shanghai Specialized, Refined, Distinctive, and Innovative SME, a Shanghai Patent Pilot Enterprise, and a R&D Institution in the Pudong New Area. The company has been honored with multiple awards, including the National Excellence Award at the 11th China Innovation & Entrepreneurship Competition; recognition as one of Shanghai's Top 50 Companies with the Most Investment Potential in 2022; the First Prize of the National Ministry of Education's Science and Technology Progress Award in 2022; the Second Prize in the 2024 "Maker China" Innovation and Entrepreneurship Competition; the Second Prize of the 2024 National Ministry of Science and Technology Huaxia Medical Science and Technology Award; the Second Prize of the 2024 Shanghai Outstanding Industry-University-Research Cooperation Project Award; and being listed as a recommended product in the medical equipment category of the "2025 Yangtze River Delta Excellent Domestic Medical Equipment and Consumables Selection."
The company's goal is to advance Irreversible Electroporation technology into indications requiring high protection of vascular and neural functions, while also developing complete solutions for mature indications. In addition to prostate cancer, BPH, and liver cancer, the company is steadily expanding its pipeline to include pancreatic cancer, thyroid cancer, COPD, and other areas.
- 2016company established(September 2016)
- 50Shanghai's Most Promising Investment Potential（2022）
- 109Intellectual Property Rights Filed（by August 2025）
- 47Utility Patent Granted（by August 2025）
- 2+1
Shanghai Science and Technology Innovation Action Plan
Shanghai Biopharmaceutical Innovation Product Key R&D Project
